Latest News

Article ID: 719983

Roswell Park's Dr. Clare Twist led an effort to develop and validate a new treatment algorithm for infants and children with neuroblastoma. In a new study in the Journal of Clinical Oncology, the team reports that many patients can safely receive less extensive therapy.

Article ID: 719191

In companion presentations at the American Society for Therapeutic Radiation Oncology Annual Meeting, doctors from Roswell Park Comprehensive Cancer Center report new evidence that low-dose aspirin and other anti-inflammatories may improve survival in patients with some head/neck and lung cancers.

Article ID: 719179

A team from Roswell Park Comprehensive Cancer Center is moving a new three-part strategy for treating advanced cancers forward with support from a DoD grant that will fund a clinical trial in patients with brain-metastatic breast cancer.

Article ID: 717425

Roswell Park researchers have received recent grant awards totaling more than $15.4 million. These competitive awards include the first National Institutes of Health funding to study a new electronic tobacco device and a state grant supporting Roswell Park's work with the national Cancer Moonshot.

Article ID: 717421

Roswell Park researchers have uncovered a biomarker that may help explain why some patients respond better than others to sorafenib, a chemotherapy commonly prescribed for patients with advanced liver cancer.

Article ID: 716823

Researchers from Roswell Park have developed a new bioinformatics-based approach for monitoring key changes in cancer cells — a data-driven method that might help to enhance and personalize cancer treatment.

Article ID: 714657

A cancer therapy based on the work of Ben Seon, PhD, at Roswell Park Comprehensive Cancer Center has been approved by the U.S. Food and Drug Administration (FDA) for patients with an aggressive form of non-Hodgkin lymphoma.

Article ID: 714361

Jens Hillengass, MD, Chief of Myeloma at Roswell Park Comprehensive Cancer Center, led an International Myeloma Working Group (IMWG) effort to compile new recommendations for imaging techniques that offer more sensitive and accurate diagnosis and monitoring for patients with multiple myeloma and other plasma-cell disorders.

Article ID: 713799

With their phase II study in patients with aggressive brain cancer now completed, the developers of the cancer immunotherapy SurVaxM report that combination therapy with the vaccine was more effective than standard therapy for nearly all patients.

Article ID: 712819

A clinical trial underway at Roswell Park Comprehensive Cancer Center will assess a brand-new immunotherapy approach — reprogramming a patient’s blood stem cells to generate a lasting supply of two types of immune cells — in patients with recurrent cancer of the ovaries, fallopian tubes or peritoneum.